496 related articles for article (PubMed ID: 17854058)
1. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy.
Wikström P; Ohlson N; Stattin P; Bergh A
Prostate; 2007 Sep; 67(12):1277-84. PubMed ID: 17597113
[TBL] [Abstract][Full Text] [Related]
4. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
5. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels.
Ohlson N; Bergh A; Stattin P; Wikström P
Prostate; 2007 Jan; 67(1):32-40. PubMed ID: 16998819
[TBL] [Abstract][Full Text] [Related]
6. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
8. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Brändström A; Westin P; Bergh A; Cajander S; Damber JE
Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
[TBL] [Abstract][Full Text] [Related]
9. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment.
Lindström P; Bergh A; Holm I; Damber JE
Prostate; 1996 Oct; 29(4):209-18. PubMed ID: 8876704
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
12. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
McAlhany SJ; Ressler SJ; Larsen M; Tuxhorn JA; Yang F; Dang TD; Rowley DR
Cancer Res; 2003 Sep; 63(18):5859-65. PubMed ID: 14522910
[TBL] [Abstract][Full Text] [Related]
13. Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats.
Johansson A; Rudolfsson SH; Wikström P; Bergh A
Endocrinology; 2005 Aug; 146(8):3463-70. PubMed ID: 15845622
[TBL] [Abstract][Full Text] [Related]
14. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
15. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
16. Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment--regulation of transcription.
Bacher M; Rausch U; Goebel HW; Polzar B; Mannherz HG; Aumüller G
Exp Clin Endocrinol; 1993; 101(2):78-86. PubMed ID: 8405143
[TBL] [Abstract][Full Text] [Related]
17. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
[TBL] [Abstract][Full Text] [Related]
19. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
20. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
